BC Week In Review | Aug 1, 2016
Company News

ANI Pharmaceuticals sales and marketing update

ANI launched a generic version of Nilandron nilutamide from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) in the U.S. The oral testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis...
BC Week In Review | Mar 16, 2015
Company News

Covis, Concordia Healthcare deal

Concordia will acquire Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis expects to record $47-$52 million in revenue related to the acquired products. The deal includes Nilandron...
BioCentury | Mar 9, 2015

Persevering with ProstVac

After more than 20 years in clinical development, including over six years in the hands of Bavarian Nordic A/S , ProstVac rilimogene galvacirepvec found a potential commercial partner in Bristol-Myers Squibb Co. Whether BMS exercises its...
BC Week In Review | Apr 15, 2013
Company News

Covis, Sanofi sales and marketing update

Sanofi granted Covis U.S. rights to Nilandron nilutamide; Plaquenil hydroxychloroquine; Rilutek riluzole; Uroxatral alfuzosin; and Kayexalate sodium polystyrene. Covis said aggregate U.S. sales in 2012 for the products were $114.6 million. Covis will market the...
BC Week In Review | Nov 4, 2002
Company News

Cell Pathways cancer news

To conserve capital, CLPA eliminated its 16-person sales force, halting sales of Nilandron nilutamide for prostate cancer from Aventis S.A. (AVE, Strasbourg, France). The company's promotion agreement with AVE was due to expire in December....
BC Week In Review | Sep 11, 2000
Clinical News

Prostvac VF: Began Phase II trials

Therion Biologics Corp. , Cambridge, Mass.   Product: Prostvac VF   Business: Cancer   Therapeutic category: Immune stimulation   Target: Immune cells   Description: Live recombinant vaccine consisting of a vaccinia virus vector encoding human prostate-specific...
BC Extra | Sep 7, 2000
Clinical News

Therion begins two Phase II trials

Under a CRADA, Therion ( Cambridge , Mass.) and the National Cancer Institute began two additional Phase II trials of Prostvac VF, a live recombinant vaccine consisting of a vaccinia virus vector encoding human prostate-specific antigen (PSA),...
BC Week In Review | Jul 10, 2000
Company News

Cell Pathways, Aventis sales and marketing update

CLPA obtained rights to market AVE's Nilandron nilutamide testosterone blocker to treat prostate cancer to urologists in the U.S. Cell Pathways Inc. (CLPA), Horsham, Penn.   Aventis S.A. (AVE), Strasbourg, France   Business: Cancer  ...
BioCentury | Jul 10, 2000

Fielding armies of antibodies

MorphoSys AG believes that the company that can produce human antibodies in the largest numbers will prevail in the battle to supply antibodies to partners. MorphoSys (NMarkt:MOR) is advancing that goal through a deal with...
BC Extra | Jul 5, 2000
Company News

Cell Pathways to market Aventis' Nilandron

CLPA obtained rights to market AVE's Nilandron nilutamide to urologists in the U.S. and Puerto Rico to treat prostate cancer. CLPA will receive a percentage of sales....
Items per page:
1 - 10 of 10